Strategic Partnerships IRBM has a history of collaborating with major industry players and global institutions (e.g., MSD, AstraZeneca, Merck, Oxford) and maintains an in-house, unified research facility. Opportunity: highlight capabilities for contracted research, asset progression from concept to candidate, and potential co-development or sponsored programs with pharma partners seeking integrated CRO support.
In-House Capabilities With comprehensive in-house capabilities spanning from discovery to preclinical readiness and an oncology-focused internal pipeline, IRBM can offer end-to-end services and share risk across early-stage programs. Opportunity: position IRBM as a one-stop partner for biotech startups needing rapid, integrated research progression and milestone-driven engagements.
Global Exposure IRBM leadership participates in high-profile events (G7 ministerial representation, AACR, BIO-Europe) and maintains a Boston office expansion. Opportunity: engage through targeted outbound at conferences and executive outreach to access international collaborations, government-funded or translational programs, and regional biotech clusters.
Digital & Outreach Readiness A redesigned website and active tech stack (Salesforce, Marketing Cloud, SEMrush, scheduling tools) indicate a focus on digital engagement and lead capture. Opportunity: offer data-driven outreach, partner enablement materials, and streamlined engagement processes to accelerate partner onboarding and collaboration opportunities.
Market Positioning Funding range ($10–$25M revenue) and a relatively small, specialized CRO context with notable collaborations suggest a niche, high-value service model. Opportunity: target mid-sized biotech firms and pharma companies seeking specialized oncology and therapeutic asset development, with tailored, milestone-based CRO packages and flexible commercial terms.